296
Participants
Start Date
April 30, 2002
Primary Completion Date
March 31, 2003
Study Completion Date
March 31, 2003
Pramlintide acetate
Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
Placebo
The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
University of Maryland Joslin Diabetes Center, Baltimore
UNC Diabetes Care Center, Durham
Medical Research Unlimited, Aventura
Ohio State Univ.-Division of Endocrinology, Diabetes, Columbus
St. James Diabetes Center, Chicago Heights
Radiant Research, St Louis
Private Practice, Lufkin
Barbara Davis Center for Childhood Diabetes, Denver
Phoenix Endocrinology Clinic, Ltd., Phoenix
Ana Ventures LLC, Mesa
East Bay Clinical Trial Center, Concord
Valley Research, Fresno
UCSD Diabetes Research Center, San Diego
Diabetes Research Institute, San Mateo
Sansum Medical Research Institute, Santa Barbara
Diablo Clinical Research, Walnut Creek
MedStar Clinical Research Center, Washington D.C.
Medical Research Unlimited, Aventura
Internal Medicine Associates, Fort Myers
Suncoast Clinical Research, New Port Richey
Children's Clinic, Tallahassee
Atlanta Diabetes Associates, Atlanta
St. James Diabetes Center, Chicago Heights
Indiana University Outpatient Clinical Research, Indianapolis
Henry Ford Health System, Detroit
Grand Rapids Associated Interns, Grand Rapids
Mercury Street Medical, Butte
Radiant Research, Portland
Physicians for Clinical Research, Camp Hill
Vanderbilt University Medical Center, Nashville
North Texas Clinical Research, Irving
Private Practice, Lufkin
Rainier Clinical Research Center, Renton
Lead Sponsor
AstraZeneca
INDUSTRY